Immuron Limited (IMC.AX)
AUD 0.06
(-1.54%)
AUD 0.06
(-1.54%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -11.48 Million AUD | 32.33% |
| 2023 | -16.97 Million AUD | 22.51% |
| 2022 | -21.9 Million AUD | 12.49% |
| 2021 | -25.02 Million AUD | -684.7% |
| 2020 | -3.18 Million AUD | 37.71% |
| 2019 | -5.11 Million AUD | -8.3% |
| 2018 | -4.72 Million AUD | -30.27% |
| 2017 | -3.62 Million AUD | -830.23% |
| 2016 | -390.12 Thousand AUD | 87.48% |
| 2015 | -3.11 Million AUD | 49.26% |
| 2014 | -6.14 Million AUD | -1943.53% |
| 2013 | -300.54 Thousand AUD | 66.01% |
| 2012 | -884.35 Thousand AUD | -17.79% |
| 2011 | -750.81 Thousand AUD | 60.11% |
| 2010 | -1.88 Million AUD | -1157.58% |
| 2009 | -149.67 Thousand AUD | 86.28% |
| 2008 | -1.09 Million AUD | -62.17% |
| 2007 | -672.64 Thousand AUD | 53.1% |
| 2006 | -1.43 Million AUD | -702.79% |
| 2005 | -178.66 Thousand AUD | 37.28% |
| 2004 | -284.86 Thousand AUD | 0.0% |
| 2002 | -576.14 Thousand AUD | -87.68% |
| 2001 | -306.98 Thousand AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | -11.65 Million AUD | 31.31% |
| 2024 Q2 | -15.04 Million AUD | 0.0% |
| 2024 Q4 | -11.48 Million AUD | 0.0% |
| 2023 FY | -16.97 Million AUD | 22.51% |
| 2023 Q2 | -18.28 Million AUD | 0.0% |
| 2023 Q4 | -16.97 Million AUD | 0.0% |
| 2022 Q4 | -21.9 Million AUD | 0.0% |
| 2022 FY | -21.9 Million AUD | 12.49% |
| 2022 Q2 | -22.6 Million AUD | 0.0% |
| 2021 FY | -25.02 Million AUD | -684.7% |
| 2021 Q4 | -25.02 Million AUD | 0.0% |
| 2021 Q2 | -26.35 Million AUD | 0.0% |
| 2020 FY | -3.18 Million AUD | 37.71% |
| 2020 Q4 | -3.18 Million AUD | 0.0% |
| 2020 Q2 | -4.66 Million AUD | 0.0% |
| 2019 Q4 | -5.11 Million AUD | 0.0% |
| 2019 FY | -5.11 Million AUD | -8.3% |
| 2019 Q2 | -4.19 Million AUD | 0.0% |
| 2018 Q4 | -4.72 Million AUD | 0.0% |
| 2018 FY | -4.72 Million AUD | -30.27% |
| 2018 Q2 | -542.28 Thousand AUD | 0.0% |
| 2017 Q4 | -3.62 Million AUD | 0.0% |
| 2017 FY | -3.62 Million AUD | -830.23% |
| 2017 Q2 | -2.42 Million AUD | 0.0% |
| 2016 FY | -390.12 Thousand AUD | 87.48% |
| 2016 Q2 | 25.84 Thousand AUD | 0.0% |
| 2016 Q4 | -390.12 Thousand AUD | 0.0% |
| 2015 Q4 | -3.11 Million AUD | 0.0% |
| 2015 Q2 | -4.57 Million AUD | 0.0% |
| 2015 FY | -3.11 Million AUD | 49.26% |
| 2014 FY | -6.14 Million AUD | -1943.53% |
| 2014 Q4 | -6.14 Million AUD | 0.0% |
| 2014 Q2 | -354.2 Thousand AUD | 0.0% |
| 2013 Q4 | -300.54 Thousand AUD | 79.23% |
| 2013 FY | -300.54 Thousand AUD | 66.01% |
| 2013 Q3 | -1.44 Million AUD | -232.13% |
| 2013 Q2 | -435.59 Thousand AUD | 0.0% |
| 2013 Q1 | -435.59 Thousand AUD | 50.74% |
| 2012 Q4 | -884.35 Thousand AUD | 0.0% |
| 2012 FY | -884.35 Thousand AUD | -17.79% |
| 2011 Q4 | -750.81 Thousand AUD | 0.0% |
| 2011 FY | -750.81 Thousand AUD | 60.11% |
| 2010 Q4 | -1.88 Million AUD | 0.0% |
| 2010 FY | -1.88 Million AUD | -1157.58% |
| 2009 FY | -149.67 Thousand AUD | 86.28% |
| 2009 Q4 | -149.67 Thousand AUD | 0.0% |
| 2008 FY | -1.09 Million AUD | -62.17% |
| 2008 Q4 | -1.09 Million AUD | 0.0% |
| 2007 Q4 | -672.64 Thousand AUD | 0.0% |
| 2007 FY | -672.64 Thousand AUD | 53.1% |
| 2006 Q4 | -1.43 Million AUD | 0.0% |
| 2006 FY | -1.43 Million AUD | -702.79% |
| 2005 FY | -178.66 Thousand AUD | 37.28% |
| 2005 Q4 | -178.66 Thousand AUD | 0.0% |
| 2004 Q4 | -284.86 Thousand AUD | 0.0% |
| 2004 FY | -284.86 Thousand AUD | 0.0% |
| 2002 Q4 | -576.14 Thousand AUD | 0.0% |
| 2002 FY | -576.14 Thousand AUD | -87.68% |
| 2001 Q4 | -306.98 Thousand AUD | 0.0% |
| 2001 FY | -306.98 Thousand AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AdAlta Limited | -845.17 Thousand AUD | -1258.754% |
| Acrux Limited | -1.45 Million AUD | -687.642% |
| Actinogen Medical Limited | -9.13 Million AUD | -25.758% |
| AnteoTech Limited | -5 Million AUD | -129.606% |
| Argenica Therapeutics Limited | -15.91 Million AUD | 27.832% |
| Arovella Therapeutics Limited | -12.71 Million AUD | 9.679% |
| Anatara Lifesciences Ltd | -982.1 Thousand AUD | -1069.304% |
| Alterity Therapeutics Limited | -12.47 Million AUD | 7.981% |
| Amplia Therapeutics Limited | -1.82 Million AUD | -529.736% |
| Avecho Biotechnology Limited | -5.32 Million AUD | -115.487% |
| Bio-Gene Technology Limited | -709.55 Thousand AUD | -1518.447% |
| Biome Australia Limited | -1.56 Million AUD | -634.82% |
| Biotron Limited | -386.06 Thousand AUD | -2874.558% |
| Botanix Pharmaceuticals Limited | -79.3 Million AUD | 85.52% |
| BTC Health Limited | -2.02 Million AUD | -467.9% |
| Chimeric Therapeutics Limited | -3.05 Million AUD | -276.149% |
| CSL Limited | 15.76 Billion AUD | 100.073% |
| Clarity Pharmaceuticals Ltd | -136.5 Million AUD | 91.587% |
| Clinuvel Pharmaceuticals Limited | -182.98 Million AUD | 93.724% |
| Cynata Therapeutics Limited | -6.2 Million AUD | -85.061% |
| Dimerix Limited | -21.99 Million AUD | 47.781% |
| EZZ Life Science Holdings Limited | -18.89 Million AUD | 39.235% |
| Hexima Limited | -2.22 Million AUD | -415.845% |
| Island Pharmaceuticals Limited | -1.23 Million AUD | -827.304% |
| Immutep Limited | -122.18 Million AUD | 90.602% |
| Imugene Limited | -91.56 Million AUD | 87.458% |
| Invex Therapeutics Ltd | -6.02 Million AUD | -90.601% |
| Memphasys Limited | 4.13 Million AUD | 377.697% |
| Nanollose Limited | -96.22 Thousand AUD | -11834.339% |
| Neuren Pharmaceuticals Limited | -17.09 Million AUD | 32.82% |
| Noxopharm Limited | -2.31 Million AUD | -395.008% |
| NeuroScientific Biopharmaceuticals Limited | -4.95 Million AUD | -131.802% |
| Nyrada Inc. | -4.76 Million AUD | -140.783% |
| Orthocell Limited | -19.92 Million AUD | 42.364% |
| PharmAust Limited | -9.71 Million AUD | -18.218% |
| Patrys Limited | -2.24 Million AUD | -412.519% |
| Paradigm Biopharmaceuticals Limited | -17.58 Million AUD | 34.682% |
| Proteomics International Laboratories Limited | -6.32 Million AUD | -81.595% |
| Prescient Therapeutics Limited | -10.16 Million AUD | -13.0% |
| PYC Therapeutics Limited | -65.76 Million AUD | 82.537% |
| Race Oncology Limited | -17.18 Million AUD | 33.19% |
| Radiopharm Theranostics Limited | -18.57 Million AUD | 38.176% |
| Recce Pharmaceuticals Ltd | -3.39 Million AUD | -238.144% |
| Starpharma Holdings Limited | -19.83 Million AUD | 42.095% |
| Telix Pharmaceuticals Limited | -105.79 Million AUD | 89.145% |
| Tissue Repair Ltd | -16.44 Million AUD | 30.152% |
| Zelira Therapeutics Limited | 5.06 Million AUD | 326.625% |